MÊME is promoting research alongside Unicancer
MÊME is on a mission to move research forward by helping Unicancer, a group of 20 non-profit private health institutes dedicated exclusively to Cancer Research (CLCC). Following our 2016 multicentre clinical trial to test all of our products, we have decided to renew our partnership with Unicancer throughout 2018. Therefore, 1% of our yearly turnover will be donated to Unicancer to help their actions towards improving treatments, research and oncology education.
At MÊME, our perspective goes much further than creating a brand of dedicated beauty products. MÊME is first and foremost a humane adventure carrying a simple goal:’improving support for women affected by cancer. This is why since launching MÊME in January 2017, we have decided to accompany and support charities and organisations who work towards improving the quality of life of those affected by cancer, a cause dear to our hearts.
Beyond beauty and dermatological quality of life,lCancer Research and the well-being of patients needs to move forward. That is why we have decided to donate 1% of our 2018 turnover to Unicancer to help their actions towards improving treatments, research and oncology education.
Both of us have unfortunately lost battles against this disease which affects every single one of us to some extent. Today, we are very proud to be able to make our contribution by supporting cancer research. We simply hope, with all our heart, that one day, no one will have to face the difficulty of losing a relative to the disease.
Judith & Juliette, MÊME Founders
We were touched by the sincerity of the young women who created MÊME Cosmetics. These founders also accepted Léon Bérard Centre’s methodology, which combines expertise and quality. This led to clinical tests, which took place in the best of conditions. Finally, offering a moment of comfort to our patients who have started a difficult care path is a real plus for us.
Pr Isabelle RAY-COQUARD, oncologist at the Léon Bérard Centre (Lyon) and specialist in gynaecologic cancers